cd3-cd56+ natural killer cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT01386619)
Timeline
Indications
Mechanism of action
- Natural killer cellSupplementation
Natural killer cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd3-cd56+ natural killer cells
- cd3-depleted/cd56+ selected natural killer cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01639456 | Phase 2 | Oct 1, 2013 | Miltenyi Biotec, Inc., University of Minnesota |
| NCT01386619 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2004 | University of Bern |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2013 |
| University of Bern | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1